EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 719 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Research with integrity – why colour blindness is a research integrity... February 28, 2023 The long road to targeting the holy grail of the immune... November 9, 2020 Easy Meals at Home October 23, 2020 Load more HOT NEWS Scientists developing urine and blood tests to detect brain tumours New Drugs Raise Old Questions about Treating Cancer during Pregnancy Common anti-inflammatory drug could boost cancer immunotherapy New on NCI’s Websites for September 2020
